Major corporate developments:

China Medical System Holdings Ltd (00867.HK): The new drug application for innovative drug Ruxolitinib Phosphate Cream has been approved for marketing in Singapore.

Insilico Medicine (03696.HK) plans to contribute RMB 302.5 million to participate in the establishment of an investment fund.

Benmo Technology (06731.HK) has signed a strategic cooperation agreement with a leading South Korean embodied intelligence robotics company.

Qinhuangdao Port Co., Ltd. (03369.HK) plans to acquire high-quality bulk cargo terminal assets in Caofeidian from Hebei Port Group and raise supporting funds.

A subsidiary of Shoucheng Holdings Limited (00697.HK) is participating in the investment of the CICC Cainiao REIT.

Dongpeng Beverage (09980.HK) has secured industrial land in Zhengzhou for RMB 98.05 million to advance the construction of its Central China production base.

CSPC Pharmaceutical Group Ltd (01093.HK): The Phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and resistant hypertension has officially launched at its first research center in China.

Chen Lin Education Group Holdings Limited (01593.HK) has entered into an acquisition framework agreement regarding a possible acquisition.

CK Life Sciences Int'l., (Holdings) Inc. (00775.HK): Sequanta Therapeutics will present the latest preclinical data for two cancer vaccines at the SITC 2026 Annual Meeting.

CStone Pharmaceuticals-B (02616.HK) has entered into a clinical development collaboration with Kimia Therapeutics to jointly advance an innovative drug candidate targeting a key repair pathway in solid tumors.

Operating results:

Yum China Holdings, Inc. (09987.HK) released its third-quarter results, with net profit of US$311 million, representing a 10% year-on-year increase.